RXRX
NASDAQ · Biotechnology
Recursion Pharmaceuticals-A
$4.05
+0.08 (+2.02%)
RXRX News8 articles
AbCellera Shares Jump 9.7% Ahead of Key Phase 2 Data Release
AbCellera (ABCL) rose 9.7% after hours as investors await Phase 2 data for ABCL635, set to release Monday. The surge adds ~$205M to market cap.
Recursion Pharmaceuticals Rallies as Short Interest and Russell Flows Drive AI-Biotech Surge
Recursion Pharmaceuticals (RXRX) rose 4.7% to $3.98, driven by heavy short interest and Russell index flows. The stock's volume surged above average as the market focused on upcoming clinical catalysts.
Recursion Pharma Rallies Past Biotech ETFs; Insider Sales and Cash Position in Focus
Recursion Pharmaceuticals (RXRX) surged 8% in a four-session week, beating biotech ETFs. Filings show insider sales, while the company's $665M cash position and upcoming data updates remain key.
Recursion Pharmaceuticals Surges on Heavy Volume, Short Interest in Focus
Recursion Pharmaceuticals (RXRX) rallied 7.95% in a holiday-shortened week, outpacing biotech ETFs, as short interest remains elevated and insider sale filings emerge.
Recursion Pharmaceuticals Gains Amid Founder Sale Filing, Short Interest Remains Elevated
Recursion Pharmaceuticals (RXRX) shares gained 3.54% on Thursday, even as the broader market slipped, with a founder's planned sale representing a tiny fraction of volume. Short interest remains high at 39.11% of float.
Recursion Stock Surges Ahead of Goldman Sachs Conference Amid AI Drug Discovery Buzz
Recursion shares surged 12% to $3.87 on heavy volume ahead of a Goldman Sachs conference, as investors await updates on clinical trials, cash runway, and partnerships amid a broader AI drug-discovery rally.
Recursion Pharmaceuticals Hits New Low Amid Revenue Drop and FDA Watch
Recursion Pharmaceuticals shares fell to a 52-week low Tuesday after Q1 revenue dropped 56% year-over-year. The AI-driven biotech firm awaits FDA feedback on key trials.
Recursion Pharma Co-Founder Gibson to Exit Board Ahead of Q1 Results
Recursion Pharmaceuticals founder Chris Gibson will leave the board at the June annual meeting. Q1 earnings due May 6; focus on cash, clinical progress, and AI platform.